Top Markets
#1 Velas Velas +367.73%
#2 Gravity Gravity +49.04%
#3 Galxe Galxe +34.81%
#4 Derive Derive +31.02%
#5 Infinity Ground Infinity Ground +29.01%
#6 Audiera Audiera +25.57%
#7 Wiki Cat Wiki Cat +25.37%
#8 Wrapped QUIL Wrapped QUIL +22.19%
#9 Aria.AI Aria.AI +21.09%
#10 Fetch.ai Fetch.ai +20.92%
Coin of the day
Velas Velas
Paramètres
Langue
FRANçAIS
Devise
USD
Thème
MultiCell Technologies, Inc. MultiCell Technologies, Inc.

MultiCell Technologies, Inc.

MCET
Classement en actions #20716
MultiCell Technologies, Inc., a biopharmaceutical company, develops novel... MultiCell Technologies, Inc., a biopharmaceutical company, develops novel therapeutics and discovery tools for the treatment of neurological disorders, hepatic disease, cancer, and interventional cardiology and peripheral vessel applications. Its product portfolio comprises MCT-125, a Phase II therapeutic candidate for the treatment of primary multiple sclerosis-related fatigue; MCT-465, a preclinical synthetic double-stranded RNA (dsRNA) therapeutic candidate and potent immune enhancer for the treatment of solid tumor cancers; and MCT-485, a discovery stage dsRNA therapeutic candidate with tumor cytolytic properties for the treatment of various cancers. The company also develops Ideal BioStent, a bioabsorbable stent for interventional cardiology and peripheral vessel applications. MultiCell Technologies, Inc. has a license agreement with Corning Incorporated and Pfizer Inc. The company was formerly known as Exten Industries, Inc. and changed its name to MultiCell Technologies, Inc. in April 2004. MultiCell Technologies, Inc. was founded in 1962 and is headquartered in Woonsocket, Rhode Island.
Prix de l'action
$0.00001
Capitalisation boursière
$50.01K
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange MultiCell Technologies, Inc. (MCET)

Catégorie

Healthcare
Capitalisation boursière
Revenus
plus
Bénéfices
Historique des prix
Ratio P/E
Ratio P/S
Ratio P/B
Marge opérationnelle
EPS
Fractionnements d’actions
Dividendes
Rendement du dividende
Actions en circulation
Ratio P/S pour MultiCell Technologies, Inc. (MCET)
Ratio P/S au March 2026 TTM : 1.01K
Selon les derniers rapports financiers et le cours de l'action de MultiCell Technologies, Inc., le ratio cours/ventes actuel (TTM) est 1.01K. À la fin de 2013, le ratio P/S était de 27.21.
Historique du ratio P/S pour MultiCell Technologies, Inc. de 2013 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
2026 (TTM) 1.01K 3,255.43%
2014 30.22 11.07%
2013 27.21 0.00%
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
3.55 -99.65%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
9.90 -99.02%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
5.40 -99.47%
US
UCB SA UCB SA
UCB SA
UCB.BR
6.14 -99.39%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
3.04 -99.70%
AU